<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d217" origId="Etanercept"><sentence id="DrugDDI.d217.s0" origId="s0" text="Specific drug interaction studies have not been conducted with ENBREL?."/><sentence id="DrugDDI.d217.s1" origId="s1" text="However, it was observed that the pharmacokinetics of ENBREL? was unaltered by concomitant methotrexate in rheumatoid arthritis patients."><entity id="DrugDDI.d217.s1.e0" origId="s1.p14" charOffset="91-103" type="drug" text="methotrexate"/></sentence><sentence id="DrugDDI.d217.s2" origId="s2" text="In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL? and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL? alone (0%)."><entity id="DrugDDI.d217.s2.e0" origId="s2.p25" charOffset="104-112" type="drug" text="anakinra"/></sentence><sentence id="DrugDDI.d217.s3" origId="s3" text="Two percent of patients treated concurrently with ENBREL? and anakinra developed neutropenia (ANC   1 x 109/L)."><entity id="DrugDDI.d217.s3.e0" origId="s3.p47" charOffset="62-70" type="drug" text="anakinra"/><entity id="DrugDDI.d217.s3.e1" origId="s3.p51" charOffset="94-110" type="drug" text="ANC   1 x 109/L"/><pair id="DrugDDI.d217.s3.p0" e1="DrugDDI.d217.s3.e0" e2="DrugDDI.d217.s3.e1" interaction="?"/></sentence><sentence id="DrugDDI.d217.s4" origId="s4" text="Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone."><entity id="DrugDDI.d217.s4.e0" origId="s4.p58" charOffset="66-79" type="drug" text="sulfasalazine"/><entity id="DrugDDI.d217.s4.e1" origId="s4.p59" charOffset="90-96" type="drug" text="ENBREL"/><entity id="DrugDDI.d217.s4.e2" origId="s4.p75" charOffset="216-222" type="drug" text="ENBREL"/><entity id="DrugDDI.d217.s4.e3" origId="s4.p77" charOffset="229-242" type="drug" text="sulfasalazine"/><pair id="DrugDDI.d217.s4.p0" e1="DrugDDI.d217.s4.e0" e2="DrugDDI.d217.s4.e1" interaction="?"/><pair id="DrugDDI.d217.s4.p1" e1="DrugDDI.d217.s4.e0" e2="DrugDDI.d217.s4.e2" interaction="?"/><pair id="DrugDDI.d217.s4.p2" e1="DrugDDI.d217.s4.e0" e2="DrugDDI.d217.s4.e3" interaction="?"/><pair id="DrugDDI.d217.s4.p3" e1="DrugDDI.d217.s4.e1" e2="DrugDDI.d217.s4.e2" interaction="?"/><pair id="DrugDDI.d217.s4.p4" e1="DrugDDI.d217.s4.e1" e2="DrugDDI.d217.s4.e3" interaction="?"/><pair id="DrugDDI.d217.s4.p5" e1="DrugDDI.d217.s4.e2" e2="DrugDDI.d217.s4.e3" interaction="?"/></sentence><sentence id="DrugDDI.d217.s5" origId="s5" text="The clinical significance of this observation is unknown."/></document>